Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Dermatology

Dermatologic Oncology

Exposure to trace elements and risk of skin cancer: A systematic review of epidemiologic studies

Cancer Epidemiology, Biomarkers & Prevention | Dec 12, 2018 Dermatologic Oncology

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Journal of Clinical Oncology | Dec 11, 2018 Dermatologic Oncology

Aggressive squamous cell carcinoma in organ transplant recipients

JAMA Dermatology | Dec 08, 2018 Dermatologic Oncology

Serum amyloid A levels in the blood of patients with atopic dermatitis and cutaneous T-cell lymphoma

The Journal of Dermatology | Dec 07, 2018 Dermatologic Oncology

High concordance of BRAF mutational status in matched primary and metastatic melanoma

Journal of Cutaneous Pathology | Nov 21, 2018 Dermatologic Oncology

Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial

Journal of Clinical Oncology | Nov 20, 2018 Dermatologic Oncology

Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness

Journal of the American Academy of Dermatology | Nov 19, 2018 Dermatologic Oncology

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Journal of Clinical Oncology | Nov 18, 2018 Dermatologic Oncology

Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600–mutated metastatic melanoma: Pooled analysis of 4 randomized clinical trials

JAMA | Nov 07, 2018 Dermatologic Oncology

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies

Cancer | Nov 07, 2018 Dermatologic Oncology

« Prev 1 … 40 41 42 43 44 … 68 Next »

Exposure to trace elements and risk of skin cancer: A systematic review of epidemiologic studies

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Aggressive squamous cell carcinoma in organ transplant recipients

Serum amyloid A levels in the blood of patients with atopic dermatitis and cutaneous T-cell lymphoma

High concordance of BRAF mutational status in matched primary and metastatic melanoma

Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial

Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600–mutated metastatic melanoma: Pooled analysis of 4 randomized clinical trials

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Pulmonary Embolism: MCQs Challenge

Pelvic Floor Disorders: Causes, Diagnosis & Treatment

More Women Experience Chronic Pain Than Men: Find Out Why

Exposure to trace elements and risk of skin cancer: A systematic review of epidemiologic studies

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Aggressive squamous cell carcinoma in organ transplant recipients

Serum amyloid A levels in the blood of patients with atopic dermatitis and cutaneous T-cell lymphoma

High concordance of BRAF mutational status in matched primary and metastatic melanoma

Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial

Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600–mutated metastatic melanoma: Pooled analysis of 4 randomized clinical trials

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Pulmonary Embolism: MCQs Challenge

Pelvic Floor Disorders: Causes, Diagnosis & Treatment

More Women Experience Chronic Pain Than Men: Find Out Why

Select Specialty

Select Topic